Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
596 patients around the world
Available in Colombia, Chile, Argentina, United States, Mexico
Bristol-Myers Squibb
596Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Non-squamous NSCLC, not amenable to treatment in curative intent.
Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation).
Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the most recent line of therapy in an adjuvant, locally advanced, or metastatic treatment setting.
Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin in combination with pemetrexed).
Inadequate organ function and/or bone marrow reserve.
Leptomeningeal metastases or spinal cord compression.
Poorly controlled systemic medical conditions.
Other protocol-defined inclusion/exclusion criteria apply.
